Stimulation of bone resorption in calvarial bones by toll-like receptor 2 through enhanced RANKL

Bone ◽  
2011 ◽  
Vol 48 ◽  
pp. S125
Author(s):  
A. Kassem⁎ ◽  
P.C. Souza ◽  
P. Lundberg ◽  
U.H. Lerner
2009 ◽  
Vol 17 (8) ◽  
pp. 662-670 ◽  
Author(s):  
Simon Heuking ◽  
Sarah Adam-Malpel ◽  
Emmanuelle Sublet ◽  
Antonio Iannitelli ◽  
Antonio di Stefano ◽  
...  

2009 ◽  
Vol 104 (3) ◽  
pp. 346-354 ◽  
Author(s):  
Price Blair ◽  
Sybille Rex ◽  
Olga Vitseva ◽  
Lea Beaulieu ◽  
Kahraman Tanriverdi ◽  
...  

2010 ◽  
Vol 51 (1) ◽  
pp. 459 ◽  
Author(s):  
Thomas G. Hauk ◽  
Marco Leibinger ◽  
Adrienne Müller ◽  
Anastasia Andreadaki ◽  
Uwe Knippschild ◽  
...  

Bone ◽  
2009 ◽  
Vol 45 (4) ◽  
pp. 650-660 ◽  
Author(s):  
Jung-Min Koh ◽  
Young-Sun Lee ◽  
Yang Soon Kim ◽  
Su-Hye Park ◽  
Seung Hun Lee ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4782
Author(s):  
Jacqueline E Mann ◽  
Megan L Ludwig ◽  
Aditi Kulkarni ◽  
Erin B Scheftz ◽  
Isabel R Murray ◽  
...  

As immunotherapies targeting the PDL1 checkpoint have become a mainstay of treatment for a subset of head and neck squamous cell carcinoma (HNSCC) patients, a detailed understanding of the mechanisms underlying PDL1-mediated immune evasion is needed. To elucidate factors regulating expression of PDL1 in HNSCC cells, a genome-wide CRISPR profiling approach was implemented to identify genes and pathways conferring altered PDL1 expression in an HNSCC cell line model. Our screen nominated several candidate PDL1 drivers, including Toll-like Receptor 2 (TLR2). Depletion of TLR2 blocks interferon-γ-induced PDL1 expression, and stimulation of TLR2 with either Staphylococcus aureus or a bacterial lipopeptide mimetic, Pam3CSK4, enhanced PDL1 expression in multiple models. The data herein demonstrate a role for TLR2 in modulating the expression of PDL1 in HNSCC models and suggest that microbiota may directly modulate immunosuppression in cancer cells. Our study represents a step toward disentangling the diverse pathways and stimuli regulating PDL1 expression in HNSCC and underscores a need for future work to characterize the complex microbiome in HNSCC patients treated with immunotherapy.


Sign in / Sign up

Export Citation Format

Share Document